2025 Q3 -tulosraportti
28 päivää sitten47 min
Tarjoustasot
Määrä
Osto
100
Myynti
Määrä
50
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 21.11. | |
| 2025 Q2 -tulosraportti | 14.8. | |
| 2025 Q1 -tulosraportti | 20.5. | |
| 2024 Q4 -tulosraportti | 1.4. | |
| 2024 Q3 -tulosraportti | 19.11.2024 |
Datan lähde: Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenASPI has now received all necessary approvals to acquire Renergen, and the deal is expected to be completed very soon. The acquisition strategically strengthens ASP Isotopes by providing access to helium and LNG production, which are critical and in-demand materials. At the same time, Renergen's Virginia Gas Project shows positive operational progress, with a production update expected in January 2026. Why isn't the stock rising significantly?- On the negative side, ASPI continues to have large losses, high costs, delays, and a high valuation, which makes the case risky and dependent on the projects succeeding in 2026. ( Future success depends on execution and commercialization ) I believe it will happen in early 2026
·1 päivä sittenBought more on these dips. Renergen acquisition is bullish but: The Renergen deal still rely on certain condition, to get founding 1. **Committed U.S. Funding:** The Renergen Phase 2 expansion project has secured **$750 million in committed senior debt funding** [1, 2]. The major portion of this funding comes from the U.S. government via the **U.S. International Development Finance Corporation (U.S. DFC)**, which committed **$500 million** in debt financing [2, 3]. The DFC is a U.S. government development finance institution [3]. 2. **Conditional Nature:** The deployment of this committed funding is **not guaranteed** and is expressly subject to the satisfaction of various **conditions precedent** [4-7]. The entire offer to acquire Renergen was conditional upon obtaining the written consent for the transfer of Renergen shares from the DFC (and other lenders) [4, 5, 8]. An announcement confirmed that the written consent to the transfer of Renergen shares from the U.S. DFC and Industrial Development Corporation of South Africa **has been obtained** [9-11]. 3. **Purpose of Conditions:** For large projects, including the construction of QLE's uranium enrichment facility (which TerraPower partially funds via a loan), disbursements are conditional upon meeting milestones like **receiving all required licenses and permits** to perform uranium enrichment in South Africa [12-14]. The DFC funding for Renergen's Phase 2 is similarly subject to standard conditions precedent being fulfilled [6, 7]. In short, the U.S. government, through the DFC, is a cornerstone lender, but the actual disbursement of the committed $500 million remains dependent on ASPI and Renergen fulfilling specific conditions related to the project's execution and financial structure [6, 7].
1 päivä sitten1 päivä sitten
·8.12.-31% in a month. Does anyone have insight into what caused it and what the future looks like for the next 6 months?·9.12.Here is a long answer based on my sources in Notebooklm: The sharp decline of -31% within one month (November 2025) was due to a perfect storm of acute risk that tested the stock's fundamental credibility. After analyzing forum discussions, company reports, and the market's reaction, here is an objective review of the reasons for the decline and the outlook for the next six months. 1. Reason for the -31% Decline (November 2025) The decline from the peak in early November (over $10) to the bottom in early December (around $6.20) [2, 3] was driven by four converging factors: 1. Geopolitical Uncertainty and Delay: The company had to postpone the deadline for the acquisition of Renergen to January 30, 2026.[4] This delay was due to a lack of regulatory approval from the South African Reserve Bank (SARB).[4] This delays the realization of the most important synergy: Renergen's LNG supply, which is intended to reduce ASPI's energy costs by up to 94% [Context]. 2. Increased Costs and Losses: ASPI's Q3 2025 results showed strong top-line growth, but also a significantly increasing operating loss and high cash burn, as the company has invested heavily in the expansion of three facilities simultaneously. This created doubt about the company's short-term profitability trajectory. 3. Short Attack and Legal Risk: The stock has been under pressure from an activist short-seller report that questioned the technology and South Africa operations. Although the company has refuted the allegations, this contributed to massive uncertainty. 4. Insider Selling: Sales of shares by management (CEO Paul Mann and COO Robert Ainscow) in November, although in accordance with pre-arranged plans to cover taxes, reinforced the impression that "insiders are fleeing" and contributed to the panic. 2. Future Outlook for the Next 6 Months (High Volatility and Major Catalysts) The stock is now in a critical and binary phase. The outlook for the next six months is extremely positive upon success, but carries significant downside risk in case of failure. A. The Two Major Catalysts (First Half 2026) Renergen Acquisition Closes (January 2026): If SARB grants final approval by January 30, ASPI will secure the helium and LNG assets that provide the necessary cost advantage for HALEU production. This is the biggest value driver and confirms that the company can reach its long-term goal of generating over $300 million in EBITDA by 2030.[5] QLE IPO: Plans to spin off the core nuclear power business, Quantum Leap Energy (QLE), and list it separately, continue to move forward. This will unlock significant value for ASPI's shareholders and finance the development of HALEU facilities with external capital. B. Technical Support and Institutional Approval Analyst Support: The day after the worst lows, the stock was significantly lifted by news that Cantor Fitzgerald initiated coverage with an "Overweight" rating and a price target of $13.00. This provides institutional validation that creates a floor for the stock. Management Stability: Founder and major shareholder Paul Mann's return as CEO (from January 19, 2026) is seen as a strong signal that management is fully focused on executing the two major transactions. C. The Geopolitical Insurance Although some on various forums, Reddit and Twitter, are concerned that Trump will cut DFC funds, ASPI's position is strategically isolated: Helium Exception: Renergen's primary export commodity, helium, is exempt from Trump's general tariffs, because it is a critical mineral the USA needs for semiconductor and aerospace technology.[6, 7] Political Insurance: Investments in QLE from Donald Trump Jr. and Eric Trump [1] create a political self-interest that makes it unlikely that the administration will sabotage this specific, strategically important project.[1] Summary for the Next 6 Months The ASPI stock is now in a Make-or-Break period. The negative price movements are behind us, but the stock will remain extremely volatile around regulatory news announcements. Upon success in January 2026, the stock will likely retest analysts' price targets of $11–$13. In case of failure, the fundamental value (cash and Si-28 contracts) will have to try to catch the fall.- ·28.11. · MuokattuThe Renergen acquisition postponed until 30januat due to bureaucracy. A small bump in the road then. Qle spinout can still be announced any time so I'm holding onto my shares. That the "Standby offer" is a safety net for the Renergen acquisition is also reassuring. The Standby Offer is an automatic "safety net" designed to save the deal if regulatory delays kill the primary merger plan. * Trigger: It activates only if the primary "Scheme of Arrangement" fails because of missed deadlines (like the Jan 30, 2026 cutoff). * The Price: Identical to the original deal (0.09196 ASPI shares for every 1 Renergen share). * The Mechanism: Instead of a "forced" merger of all shareholders at once, ASPI makes a direct offer to buy shares from anyone willing to sell. * Key Difference: It is unconditional. ASPI does not need a minimum number of votes; they will buy whatever shares are tendered to them, ensuring they can still acquire the majority of the company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
28 päivää sitten47 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenASPI has now received all necessary approvals to acquire Renergen, and the deal is expected to be completed very soon. The acquisition strategically strengthens ASP Isotopes by providing access to helium and LNG production, which are critical and in-demand materials. At the same time, Renergen's Virginia Gas Project shows positive operational progress, with a production update expected in January 2026. Why isn't the stock rising significantly?- On the negative side, ASPI continues to have large losses, high costs, delays, and a high valuation, which makes the case risky and dependent on the projects succeeding in 2026. ( Future success depends on execution and commercialization ) I believe it will happen in early 2026·1 päivä sittenBought more on these dips. Renergen acquisition is bullish but: The Renergen deal still rely on certain condition, to get founding 1. **Committed U.S. Funding:** The Renergen Phase 2 expansion project has secured **$750 million in committed senior debt funding** [1, 2]. The major portion of this funding comes from the U.S. government via the **U.S. International Development Finance Corporation (U.S. DFC)**, which committed **$500 million** in debt financing [2, 3]. The DFC is a U.S. government development finance institution [3]. 2. **Conditional Nature:** The deployment of this committed funding is **not guaranteed** and is expressly subject to the satisfaction of various **conditions precedent** [4-7]. The entire offer to acquire Renergen was conditional upon obtaining the written consent for the transfer of Renergen shares from the DFC (and other lenders) [4, 5, 8]. An announcement confirmed that the written consent to the transfer of Renergen shares from the U.S. DFC and Industrial Development Corporation of South Africa **has been obtained** [9-11]. 3. **Purpose of Conditions:** For large projects, including the construction of QLE's uranium enrichment facility (which TerraPower partially funds via a loan), disbursements are conditional upon meeting milestones like **receiving all required licenses and permits** to perform uranium enrichment in South Africa [12-14]. The DFC funding for Renergen's Phase 2 is similarly subject to standard conditions precedent being fulfilled [6, 7]. In short, the U.S. government, through the DFC, is a cornerstone lender, but the actual disbursement of the committed $500 million remains dependent on ASPI and Renergen fulfilling specific conditions related to the project's execution and financial structure [6, 7].
- 1 päivä sitten1 päivä sitten
- ·8.12.-31% in a month. Does anyone have insight into what caused it and what the future looks like for the next 6 months?·9.12.Here is a long answer based on my sources in Notebooklm: The sharp decline of -31% within one month (November 2025) was due to a perfect storm of acute risk that tested the stock's fundamental credibility. After analyzing forum discussions, company reports, and the market's reaction, here is an objective review of the reasons for the decline and the outlook for the next six months. 1. Reason for the -31% Decline (November 2025) The decline from the peak in early November (over $10) to the bottom in early December (around $6.20) [2, 3] was driven by four converging factors: 1. Geopolitical Uncertainty and Delay: The company had to postpone the deadline for the acquisition of Renergen to January 30, 2026.[4] This delay was due to a lack of regulatory approval from the South African Reserve Bank (SARB).[4] This delays the realization of the most important synergy: Renergen's LNG supply, which is intended to reduce ASPI's energy costs by up to 94% [Context]. 2. Increased Costs and Losses: ASPI's Q3 2025 results showed strong top-line growth, but also a significantly increasing operating loss and high cash burn, as the company has invested heavily in the expansion of three facilities simultaneously. This created doubt about the company's short-term profitability trajectory. 3. Short Attack and Legal Risk: The stock has been under pressure from an activist short-seller report that questioned the technology and South Africa operations. Although the company has refuted the allegations, this contributed to massive uncertainty. 4. Insider Selling: Sales of shares by management (CEO Paul Mann and COO Robert Ainscow) in November, although in accordance with pre-arranged plans to cover taxes, reinforced the impression that "insiders are fleeing" and contributed to the panic. 2. Future Outlook for the Next 6 Months (High Volatility and Major Catalysts) The stock is now in a critical and binary phase. The outlook for the next six months is extremely positive upon success, but carries significant downside risk in case of failure. A. The Two Major Catalysts (First Half 2026) Renergen Acquisition Closes (January 2026): If SARB grants final approval by January 30, ASPI will secure the helium and LNG assets that provide the necessary cost advantage for HALEU production. This is the biggest value driver and confirms that the company can reach its long-term goal of generating over $300 million in EBITDA by 2030.[5] QLE IPO: Plans to spin off the core nuclear power business, Quantum Leap Energy (QLE), and list it separately, continue to move forward. This will unlock significant value for ASPI's shareholders and finance the development of HALEU facilities with external capital. B. Technical Support and Institutional Approval Analyst Support: The day after the worst lows, the stock was significantly lifted by news that Cantor Fitzgerald initiated coverage with an "Overweight" rating and a price target of $13.00. This provides institutional validation that creates a floor for the stock. Management Stability: Founder and major shareholder Paul Mann's return as CEO (from January 19, 2026) is seen as a strong signal that management is fully focused on executing the two major transactions. C. The Geopolitical Insurance Although some on various forums, Reddit and Twitter, are concerned that Trump will cut DFC funds, ASPI's position is strategically isolated: Helium Exception: Renergen's primary export commodity, helium, is exempt from Trump's general tariffs, because it is a critical mineral the USA needs for semiconductor and aerospace technology.[6, 7] Political Insurance: Investments in QLE from Donald Trump Jr. and Eric Trump [1] create a political self-interest that makes it unlikely that the administration will sabotage this specific, strategically important project.[1] Summary for the Next 6 Months The ASPI stock is now in a Make-or-Break period. The negative price movements are behind us, but the stock will remain extremely volatile around regulatory news announcements. Upon success in January 2026, the stock will likely retest analysts' price targets of $11–$13. In case of failure, the fundamental value (cash and Si-28 contracts) will have to try to catch the fall.
- ·28.11. · MuokattuThe Renergen acquisition postponed until 30januat due to bureaucracy. A small bump in the road then. Qle spinout can still be announced any time so I'm holding onto my shares. That the "Standby offer" is a safety net for the Renergen acquisition is also reassuring. The Standby Offer is an automatic "safety net" designed to save the deal if regulatory delays kill the primary merger plan. * Trigger: It activates only if the primary "Scheme of Arrangement" fails because of missed deadlines (like the Jan 30, 2026 cutoff). * The Price: Identical to the original deal (0.09196 ASPI shares for every 1 Renergen share). * The Mechanism: Instead of a "forced" merger of all shareholders at once, ASPI makes a direct offer to buy shares from anyone willing to sell. * Key Difference: It is unconditional. ASPI does not need a minimum number of votes; they will buy whatever shares are tendered to them, ensuring they can still acquire the majority of the company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
100
Myynti
Määrä
50
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 21.11. | |
| 2025 Q2 -tulosraportti | 14.8. | |
| 2025 Q1 -tulosraportti | 20.5. | |
| 2024 Q4 -tulosraportti | 1.4. | |
| 2024 Q3 -tulosraportti | 19.11.2024 |
Datan lähde: Quartr
2025 Q3 -tulosraportti
28 päivää sitten47 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 21.11. | |
| 2025 Q2 -tulosraportti | 14.8. | |
| 2025 Q1 -tulosraportti | 20.5. | |
| 2024 Q4 -tulosraportti | 1.4. | |
| 2024 Q3 -tulosraportti | 19.11.2024 |
Datan lähde: Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenASPI has now received all necessary approvals to acquire Renergen, and the deal is expected to be completed very soon. The acquisition strategically strengthens ASP Isotopes by providing access to helium and LNG production, which are critical and in-demand materials. At the same time, Renergen's Virginia Gas Project shows positive operational progress, with a production update expected in January 2026. Why isn't the stock rising significantly?- On the negative side, ASPI continues to have large losses, high costs, delays, and a high valuation, which makes the case risky and dependent on the projects succeeding in 2026. ( Future success depends on execution and commercialization ) I believe it will happen in early 2026·1 päivä sittenBought more on these dips. Renergen acquisition is bullish but: The Renergen deal still rely on certain condition, to get founding 1. **Committed U.S. Funding:** The Renergen Phase 2 expansion project has secured **$750 million in committed senior debt funding** [1, 2]. The major portion of this funding comes from the U.S. government via the **U.S. International Development Finance Corporation (U.S. DFC)**, which committed **$500 million** in debt financing [2, 3]. The DFC is a U.S. government development finance institution [3]. 2. **Conditional Nature:** The deployment of this committed funding is **not guaranteed** and is expressly subject to the satisfaction of various **conditions precedent** [4-7]. The entire offer to acquire Renergen was conditional upon obtaining the written consent for the transfer of Renergen shares from the DFC (and other lenders) [4, 5, 8]. An announcement confirmed that the written consent to the transfer of Renergen shares from the U.S. DFC and Industrial Development Corporation of South Africa **has been obtained** [9-11]. 3. **Purpose of Conditions:** For large projects, including the construction of QLE's uranium enrichment facility (which TerraPower partially funds via a loan), disbursements are conditional upon meeting milestones like **receiving all required licenses and permits** to perform uranium enrichment in South Africa [12-14]. The DFC funding for Renergen's Phase 2 is similarly subject to standard conditions precedent being fulfilled [6, 7]. In short, the U.S. government, through the DFC, is a cornerstone lender, but the actual disbursement of the committed $500 million remains dependent on ASPI and Renergen fulfilling specific conditions related to the project's execution and financial structure [6, 7].
- 1 päivä sitten1 päivä sitten
- ·8.12.-31% in a month. Does anyone have insight into what caused it and what the future looks like for the next 6 months?·9.12.Here is a long answer based on my sources in Notebooklm: The sharp decline of -31% within one month (November 2025) was due to a perfect storm of acute risk that tested the stock's fundamental credibility. After analyzing forum discussions, company reports, and the market's reaction, here is an objective review of the reasons for the decline and the outlook for the next six months. 1. Reason for the -31% Decline (November 2025) The decline from the peak in early November (over $10) to the bottom in early December (around $6.20) [2, 3] was driven by four converging factors: 1. Geopolitical Uncertainty and Delay: The company had to postpone the deadline for the acquisition of Renergen to January 30, 2026.[4] This delay was due to a lack of regulatory approval from the South African Reserve Bank (SARB).[4] This delays the realization of the most important synergy: Renergen's LNG supply, which is intended to reduce ASPI's energy costs by up to 94% [Context]. 2. Increased Costs and Losses: ASPI's Q3 2025 results showed strong top-line growth, but also a significantly increasing operating loss and high cash burn, as the company has invested heavily in the expansion of three facilities simultaneously. This created doubt about the company's short-term profitability trajectory. 3. Short Attack and Legal Risk: The stock has been under pressure from an activist short-seller report that questioned the technology and South Africa operations. Although the company has refuted the allegations, this contributed to massive uncertainty. 4. Insider Selling: Sales of shares by management (CEO Paul Mann and COO Robert Ainscow) in November, although in accordance with pre-arranged plans to cover taxes, reinforced the impression that "insiders are fleeing" and contributed to the panic. 2. Future Outlook for the Next 6 Months (High Volatility and Major Catalysts) The stock is now in a critical and binary phase. The outlook for the next six months is extremely positive upon success, but carries significant downside risk in case of failure. A. The Two Major Catalysts (First Half 2026) Renergen Acquisition Closes (January 2026): If SARB grants final approval by January 30, ASPI will secure the helium and LNG assets that provide the necessary cost advantage for HALEU production. This is the biggest value driver and confirms that the company can reach its long-term goal of generating over $300 million in EBITDA by 2030.[5] QLE IPO: Plans to spin off the core nuclear power business, Quantum Leap Energy (QLE), and list it separately, continue to move forward. This will unlock significant value for ASPI's shareholders and finance the development of HALEU facilities with external capital. B. Technical Support and Institutional Approval Analyst Support: The day after the worst lows, the stock was significantly lifted by news that Cantor Fitzgerald initiated coverage with an "Overweight" rating and a price target of $13.00. This provides institutional validation that creates a floor for the stock. Management Stability: Founder and major shareholder Paul Mann's return as CEO (from January 19, 2026) is seen as a strong signal that management is fully focused on executing the two major transactions. C. The Geopolitical Insurance Although some on various forums, Reddit and Twitter, are concerned that Trump will cut DFC funds, ASPI's position is strategically isolated: Helium Exception: Renergen's primary export commodity, helium, is exempt from Trump's general tariffs, because it is a critical mineral the USA needs for semiconductor and aerospace technology.[6, 7] Political Insurance: Investments in QLE from Donald Trump Jr. and Eric Trump [1] create a political self-interest that makes it unlikely that the administration will sabotage this specific, strategically important project.[1] Summary for the Next 6 Months The ASPI stock is now in a Make-or-Break period. The negative price movements are behind us, but the stock will remain extremely volatile around regulatory news announcements. Upon success in January 2026, the stock will likely retest analysts' price targets of $11–$13. In case of failure, the fundamental value (cash and Si-28 contracts) will have to try to catch the fall.
- ·28.11. · MuokattuThe Renergen acquisition postponed until 30januat due to bureaucracy. A small bump in the road then. Qle spinout can still be announced any time so I'm holding onto my shares. That the "Standby offer" is a safety net for the Renergen acquisition is also reassuring. The Standby Offer is an automatic "safety net" designed to save the deal if regulatory delays kill the primary merger plan. * Trigger: It activates only if the primary "Scheme of Arrangement" fails because of missed deadlines (like the Jan 30, 2026 cutoff). * The Price: Identical to the original deal (0.09196 ASPI shares for every 1 Renergen share). * The Mechanism: Instead of a "forced" merger of all shareholders at once, ASPI makes a direct offer to buy shares from anyone willing to sell. * Key Difference: It is unconditional. ASPI does not need a minimum number of votes; they will buy whatever shares are tendered to them, ensuring they can still acquire the majority of the company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
100
Myynti
Määrä
50
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt